ARD Podcast – Details, episodes & analysis

Join our host Dr. Fabian Proft, ARD's Social Media Advisor, as he discusses the updated 2023 EULAR recommendations for imaging in large vessel vasculitis (LVV) with Professor Christian Dejaco and Dr. Milena Bond, the lead authors of the manuscript. This episode covers the latest evidence on ultrasound, MRI, CT, and FDG-PET for diagnosing and monitoring LVV.

Key highlights include:

• Ultrasound as the first-line imaging test for giant cell arteritis.
• Preferred imaging modalities for Takayasu arteritis.
• Use of imaging for assessing vessel abnormalities and long-term monitoring.
• Insights into the research agenda for imaging in large vessel vasculitides.

Tune in to learn how these updates aim to enhance patient care and stay informed on the latest developments in rheumatology imaging. Please subscribe to the ARD podcast on all podcast platforms, including Apple Podcast, Stitcher and Spotify. If you enjoy the show, feel free to leave us a comment or a review on the podcast iTunes page - https://podcasts.apple.com/gb/podcast/ard-podcast/id1171058059 .

This podcast brings you the 2023 update on the EULAR recommendations for the management of systemic lupus erythematosus (SLE).

ARD's Social Media Advisor, Professor Laura Andreoli, speaks to Professors Antonios Fanouriakis and Dimitrios Boumpas, both from the "Attikon" University Hospital, National and Kapodistrian University of Athens, Greece, two of the authors of the recommendations paper. Read it on the ARD website: https://ard.bmj.com/content/83/1/15.

Please subscribe to the ARD podcast on all podcast platforms, including Apple Podcast, Stitcher and Spotify. If you enjoy the show, feel free to leave us a comment or a review on the podcast iTunes page - https://podcasts.apple.com/gb/podcast/ard-podcast/id1171058059 .

Dr. Felice Rivellese from the Center of Experimental Medicine and Rheumatology at the Queen Mary University in London discusses the results of his presentation at the ACR 2019 with Dr. Caroline Ospelt. In a subanalysis of the pathobiology of the Early Arthitis Cohort (PEAC), Rivellese at al could show that B cell-rich synovitis is associated with disease severity and radiographic progression, in particular, if B cell infiltrates persist after cDMARD treatment.

This randomised, double-blind, placebo-controlled trial by Kroon et al has demonstrated a substantial improvement in painful hand OA with signs of inflammation following six weeks of low-dose prednisolone.

Atul Deodhar, from the Oregon Health & Science University, provides an overview of recent clinical trial results in the area of seronegative Spondylarthritis. He presented the 24-week data of Guselkumab in active psoriatic arthritis patients in the DISCOVER-1 study and compared the phase 3 trials in non-radiographic SpA patients on Ixekizumab (COAST-X) and Secukinumab (PREVENT) with up to 52 week data available.

TULIP 2: Efficacy and Safety of Anifrolumab in Patients with Moderate to Severe Systemic Lupus Erythematosus: Results of the Second Phase 3 Randomized Controlled Trial.

In this second phase 3 trial, the primary endpoint, BICLA, was achieved, and anifrolumab was superior to placebo for multiple secondary efficacy endpoints, including SRI(4), skin disease, and oral corticosteroid tapering.

TULIP 1: A Phase 3 Randomized Controlled Trial of Anifrolumab in Patients with Moderate to Severe Systemic Lupus Erythematosus

In this first phase 3 trial, the primary endpoint, SRI(4), was not achieved, but numeric improvements achieving thresholds associated with clinical benefit were observed for BICLA, oral corticosteroid tapering and other organ-specific endpoints.

The paper discussed in this podcast provides an approach, using Capture Hi-C data, to link genetic associations to potential causal genes and assess the potential of drug repurposing in three rheumatic diseases. This has the potential to identify genes which are functionally relevant and the target of existing therapies, which could provide new ways to treat patients, enhancing their quality of life and reducing the economic impact on healthcare providers.

Read the full paper on the ARD website: https://ard.bmj.com/content/78/8/1127.

The highlights of the latest update of the EULAR recommendations for the management of systemic lupus erythematosus (SLE), based on emerging new evidence, are discussed in this podcast.

Read the full paper on the ARD website: https://ard.bmj.com/content/78/6/736.

Musculoskeletal diseases have increased significantly between 2000 and 2015 and are now the second cause of years lived with disability worldwide, a study recently published by ARD concludes. The paper also adds that the burden is higher in Europe. “The richest the country, the highest the burden of musculoskeletal diseases”, says the leading author. Professor Laurent Arnaud and Dr Eden Sebbag(Department of Rheumatology - Centre National de Référence des Maladies Systémiques Rares Est Sud-Ouest, Hôpitaux Universitaires de Strasbourg, France) discuss the details of the study with ARD's Social Media Advisor, Dr Paul Studenic.

Read the full paper: https://ard.bmj.com/content/78/6/844.